Hafsa Bahaar, S. Giridhar Reddy, B. Siva Kumar, K. Prashanthi and H.C. Ananda Murthy
1Department of Biotechnology, Ramaiah University of Applied Sciences, Bengaluru, 560054, India
2Department of Chemistry, Amrita School of Engineering, Bengaluru, Amrita Vishwa Vidyapeetham, 560035, India
3Department of Applied Chemistry, School of Natural Science, Adama Science and Technology University, Adama, 1888, Ethiopia
A new nanocarrier was developed to address the debilitating side effects associated with cancer treatment, specifically for delivering Sorafenib (SF). This nanocarrier utilises biodegradable polymers, which present a promising approach to anti-cancer therapy by enabling controlled drug release and reduced toxicity. The design of the nanocarrier includes Fe3O4 nanoparticles, Sodium alginate, Lignosulphonic acid, Polyethylene glycol, SF drug, and a MgAl layered double hydroxide coating. The nanocarrier was extensively characterised using various techniques, including FT-IR, TGA, and FESEM. Notably, the IONP nanocarrier demonstrated remarkable superiority in the controlled release of SF compared to other variations. The chemical interactions among the components of the nanocarrier significantly contributed to its enhanced stability, as evidenced by thermogravimetric analysis. Furthermore, XRD analysis confirmed the crystalline nature of the final samples. The FESEM images provided visual confirmation of the morphology of the nanocarrier combinations. Additionally, kinetic models verified the sustained release of SF from the composite alginate matrix. These findings collectively highlight the potential of this nanocarrier system as an effective approach for delivering SF drug in cancer treatment while minimising side effects.
Received: 07 Apr 2023
Revised: 11 Jun 2023
Accepted: 15 Jun 2023
Published online: 30 Jun 2023
Article type:
Research Paper
DOI:
10.30919/es914
Volume:
24
Article :
914
Citation:
Engineered Science, 2023, 24, 914
Permissions:
Copyright
Number of downloads:
4363
Citation Information:
25
Description:
Developing a novel nanocarrier for delivering Sorafenib (SF) in lung cancer treatment can potentiall....
Developing a novel nanocarrier for delivering Sorafenib (SF) in lung cancer treatment can potentially reduce debilitating side effects associated with SF treatment.
This article is cited by 25 publications.
This article is cited by 25 publications.
Copyright © 2025 Engineered Science Publisher, All Rights Reserved